IRLAB Therapeutics AB (OSTO:IRLAB A) Interest Expense: kr-14.36 Mil (TTM As of Mar. 2026)


OSTO:IRLAB A IRLAB Therapeutics AB OSTO:IRLAB A
36 GF Score
Price kr1.29
GF Value kr11.76
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is IRLAB Therapeutics AB Interest Expense?

IRLAB Therapeutics AB OSTO:IRLAB A -1.83% 36 Interest Expense is kr-14.36 Mil as of Mar. 2026. GuruFocus rates OSTO:IRLAB A with a GF Score™ of 36/100 and a GF Value™ of kr11.76 (Possible Value Trap). The stock has 6 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. IRLAB Therapeutics AB's interest expense for the three months ended in Mar. 2026 was kr -1.94 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was kr-14.36 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. IRLAB Therapeutics AB's Operating Income for the three months ended in Mar. 2026 was kr 10.73 Mil. IRLAB Therapeutics AB's Interest Expense for the three months ended in Mar. 2026 was kr -1.94 Mil. IRLAB Therapeutics AB's Interest Coverage for the quarter that ended in Mar. 2026 was 5.54. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

IRLAB Therapeutics AB  (OSTO:IRLAB A) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

IRLAB Therapeutics AB's Interest Expense for the three months ended in Mar. 2026 was kr-1.94 Mil. Its Operating Income for the three months ended in Mar. 2026 was kr10.73 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2026 was kr0.00 Mil.

IRLAB Therapeutics AB's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

Interest Coverage=-1* Operating Income (Q: Mar. 2026 )/Interest Expense (Q: Mar. 2026 )
=-1*10.729/-1.936
=5.54

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

IRLAB Therapeutics AB Interest Expense Historical Data

* Premium members only.

The historical data trend for IRLAB Therapeutics AB's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

IRLAB Therapeutics AB Interest Expense Chart

IRLAB Therapeutics AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Interest Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.37 -0.30 -0.20 -10.48 -17.99

IRLAB Therapeutics AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.57 -6.99 -3.38 -2.06 -1.94
OSTO:IRLAB A
36GF Score
IRLAB Therapeutics AB OSTO:IRLAB A
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

IRLAB Therapeutics AB Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-14.36 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of kr-14.36 Mil mean?
IRLAB Therapeutics AB (OSTO:IRLAB A) has a Interest Expense of kr-14.36 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on IRLAB Therapeutics AB and its competitors.
Is IRLAB Therapeutics AB's Interest Expense too high?
IRLAB Therapeutics AB's current Interest Expense is kr-14.36 Mil. Overall, IRLAB Therapeutics AB has a GF Score™ of 36/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does IRLAB Therapeutics AB's Interest Expense compare to VRTX and REGN?
IRLAB Therapeutics AB's Interest Expense of kr-14.36 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Biotechnology company?
A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on IRLAB Therapeutics AB and its competitors. IRLAB Therapeutics AB's current Interest Expense is kr-14.36 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IRLAB Therapeutics AB stock overvalued right now?
Based on GuruFocus' analysis, IRLAB Therapeutics AB (OSTO:IRLAB A) is currently considered Possible Value Trap. The stock's GF Value™ is kr11.76, compared to a current price of kr1.29 — trading 89% below its estimated fair value. The current Interest Expense is kr-14.36 Mil. IRLAB Therapeutics AB's overall GF Score™ is 36/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For IRLAB Therapeutics AB (OSTO:IRLAB A), the current Interest Expense is kr-14.36 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is IRLAB Therapeutics AB (OSTO:IRLAB A) Overvalued in 2026?

Based on GuruFocus' analysis, IRLAB Therapeutics AB stock appears to be undervalued. The current stock price of kr1.29 is trading 89% below its estimated GF Value™ of kr11.76. GuruFocus considers IRLAB Therapeutics AB to be Possible Value Trap.

Key valuation signals for OSTO:IRLAB A:

  • Interest Expense: kr-14.36 Mil
  • GF Value™: kr11.76 vs. price of kr1.29 (89% below fair value)
  • GF Score™: 36/100 with 6 warning signs

No single metric tells the full story. See the OSTO:IRLAB A stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

IRLAB Therapeutics AB Business Description

Other Exchanges 6IRA:Germany
Address Arvid Wallgren Backe 20, Goteborg, SWE, 413 46
IRLAB Therapeutics AB is a drug discovery and development company providing novel treatments for disorders of the brain. The company focuses on treatments and quality of life for patients with neurological and psychiatric illnesses. It is engaged in programs targeting core dysfunctions in Parkinson's disease and dementias. In addition, it is also involved in the clinical development of novel compounds that aims to offer improved clinical benefit for patients with Parkinson's disease. The company's current clinical candidates, mesdopetam (IRL790) and pirepemat (IRL752), both of which have successfully gone through Phase I safety and Phase IIa efficacy proof-of-concept studies, are now in Phase IIb trials.
36GF Score

Get the complete analysis for OSTO:IRLAB A

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr1.29
Price
kr11.76
GF Value